Drugs / Live Attenuated Varicella Vaccine
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT05669625 | Dec 2022 → Apr 2024 overdue | chickenpox | China National Biotec Group Company Limited | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02981836 | Aug 2016 → Jun 2017 | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Completed | Met primary |
| Phase 48 trials · 1 met primary | ||||||
| Phase 4 | NCT06484686 | Sep 2024 → Dec 2028 expected | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05460429 | Jul 2022 → Mar 2023 | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT05470855 | Jul → Nov 2022 | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT05095701 | Dec 2021 overdue | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05526820 | Apr 2021 | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Completed | Met primary |
| Phase 4 | NCT01982409 | Jun 2013 → Jan 2018 | chickenpox | Changchun Changsheng Life Science and Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT01815073 | Mar → Jul 2013 | Japanese encephalitis, chickenpox | Changchun Keygen Biological Products Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01817270 | Mar → Aug 2013 | chickenpox | Changchun Keygen Biological Products Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03555071 Comparator | Apr 2014 → May 2017 | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-10-25 | Sinovac Biotech Co., Ltd | Results 科兴水痘疫苗安全性更优 国际学术期刊《疫苗》发表最新研究 sinovac.com ↗
研究结果显示科兴水痘减毒活疫苗免疫原性达到非劣效性标准，且安全性优于对照疫苗。 |
| 2023-01-09 | Sinovac Biotech Co., Ltd | Results 1岁儿童同时接种科兴甲肝灭活疫苗和水痘减毒活疫苗具有良好安全性和免疫原性 sinovac.com ↗
研究结果显示，同时接种两种疫苗安全性和免疫原性良好，儿童1岁龄可以同时接种水痘减毒活疫苗和甲肝灭活疫苗。 |
| 2022-06-10 | Sinovac Biotech Co., Ltd | Results 最新研究表明SINOVAC科兴水痘减毒活疫苗单剂接种的免疫持久性、加强免疫的免疫原性和安全性良好 sinovac.com ↗
研究结果显示，接种单剂SINOVAC科兴水痘减毒活疫苗具有良好的免疫持久性，完成第二剂次接种后抗体阳性率 高达100% ，且疫苗具有良好的安全性。 |
| 2019-12-29 | Sinovac Biotech Co., Ltd | Regulatory 科兴水痘减毒活疫苗获药品注册批件 sinovac.com ↗
2019年12月18日，科兴（大连）疫苗技术有限公司自主研发的预防用生物制品——水痘减毒活疫苗生产注册申请获 国家药品监督管理局（NMPA） 批准，取得药品注册批件。 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-25 | Sinovac Biotech Co., Ltd | 科兴水痘疫苗安全性更优 国际学术期刊《疫苗》发表最新研究 sinovac.com ↗ |
| 2023-01-09 | Sinovac Biotech Co., Ltd | 1岁儿童同时接种科兴甲肝灭活疫苗和水痘减毒活疫苗具有良好安全性和免疫原性 sinovac.com ↗ |
| 2022-06-10 | Sinovac Biotech Co., Ltd | 最新研究表明SINOVAC科兴水痘减毒活疫苗单剂接种的免疫持久性、加强免疫的免疫原性和安全性良好 sinovac.com ↗ |
| 2019-12-29 | Sinovac Biotech Co., Ltd | 科兴水痘减毒活疫苗获药品注册批件 sinovac.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live Attenuated Varicella Vaccine | “Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0” NCT03555071 ↗ |
| Known as | VarV | “AIM: To evaluate the immunogenicity and safety of a booster dose of live attenuated varicella vaccine (VarV) manufactured by Sinovac (Dalian) Vaccine Technology Co. Ltd., and...” PMID 35632416 ↗ Apr 20221“This study aimed to evaluate the immunogenicity and safety of co-administration with live attenuated varicella vaccine (VarV) and inactivated hepatitis A vaccine (HepA) among...” PMID 36593652 ↗ Jan 2023 |
| Modality | Vaccine | “Live Attenuated Varicella Vaccine” NCT01815073 ↗ |
| Route | Other | “the hypodermic injection” NCT01817270 ↗ |